IL4 and asthma: The approved humanized monoclonal antibodies (mAbs) for the treatment of asthma are targeted against IgE (omalizumab), IL-5 (mepolizumab and reslizumab), IL-5 receptor α (IL-5Rα; benralizumab), and IL-4/IL-13 (dupilumab) [24,25,26,27].